Porton Pharma Solutions Ltd. (300363.SZ)
CNY 17.08
(0.59%)
CNY 17.08
(0.59%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.17 Billion CNY | -13.56% |
| 2022 | 3.67 Billion CNY | 54.55% |
| 2021 | 2.37 Billion CNY | 115.27% |
| 2020 | 1.1 Billion CNY | 23.85% |
| 2019 | 891.16 Million CNY | -40.24% |
| 2018 | 1.49 Billion CNY | 6.6% |
| 2017 | 1.39 Billion CNY | -6.83% |
| 2016 | 1.5 Billion CNY | 25.13% |
| 2015 | 1.19 Billion CNY | 22.37% |
| 2014 | 980.53 Million CNY | 88.69% |
| 2013 | 519.66 Million CNY | 12.16% |
| 2012 | 463.32 Million CNY | 41.13% |
| 2011 | 328.3 Million CNY | 10.46% |
| 2010 | 297.2 Million CNY | 33.3% |
| 2009 | 222.95 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.16 Billion CNY | -3.07% |
| 2024 Q1 | 3.26 Billion CNY | 2.79% |
| 2024 Q3 | 3.36 Billion CNY | 6.52% |
| 2023 Q4 | 3.17 Billion CNY | 12.15% |
| 2023 FY | 3.17 Billion CNY | -13.56% |
| 2023 Q3 | 2.83 Billion CNY | -12.25% |
| 2023 Q2 | 3.22 Billion CNY | -0.49% |
| 2023 Q1 | 3.24 Billion CNY | -11.74% |
| 2022 Q2 | 4.23 Billion CNY | 41.04% |
| 2022 Q1 | 3 Billion CNY | 26.43% |
| 2022 FY | 3.67 Billion CNY | 54.55% |
| 2022 Q4 | 3.67 Billion CNY | -11.12% |
| 2022 Q3 | 4.13 Billion CNY | -2.49% |
| 2021 Q3 | 1.85 Billion CNY | 10.04% |
| 2021 Q1 | 1.2 Billion CNY | 9.53% |
| 2021 FY | 2.37 Billion CNY | 115.27% |
| 2021 Q4 | 2.37 Billion CNY | 28.13% |
| 2021 Q2 | 1.68 Billion CNY | 39.39% |
| 2020 Q2 | 1 Billion CNY | 10.53% |
| 2020 FY | 1.1 Billion CNY | 23.85% |
| 2020 Q4 | 1.1 Billion CNY | -1.4% |
| 2020 Q3 | 1.11 Billion CNY | 10.87% |
| 2020 Q1 | 913.46 Million CNY | 2.5% |
| 2019 Q1 | 1.34 Billion CNY | -9.5% |
| 2019 Q3 | 1.04 Billion CNY | -11.3% |
| 2019 FY | 891.16 Million CNY | -40.24% |
| 2019 Q4 | 891.16 Million CNY | -14.88% |
| 2019 Q2 | 1.18 Billion CNY | -12.54% |
| 2018 Q4 | 1.49 Billion CNY | -0.37% |
| 2018 Q3 | 1.49 Billion CNY | -12.51% |
| 2018 Q2 | 1.71 Billion CNY | 30.52% |
| 2018 Q1 | 1.31 Billion CNY | -6.29% |
| 2018 FY | 1.49 Billion CNY | 6.6% |
| 2017 Q2 | 1.29 Billion CNY | -19.69% |
| 2017 Q1 | 1.61 Billion CNY | 7.67% |
| 2017 FY | 1.39 Billion CNY | -6.83% |
| 2017 Q4 | 1.39 Billion CNY | 14.2% |
| 2017 Q3 | 1.22 Billion CNY | -5.65% |
| 2016 Q1 | 1.22 Billion CNY | 1.89% |
| 2016 Q2 | 1.4 Billion CNY | 15.0% |
| 2016 Q3 | 1.35 Billion CNY | -3.84% |
| 2016 FY | 1.5 Billion CNY | 25.13% |
| 2016 Q4 | 1.5 Billion CNY | 11.05% |
| 2015 FY | 1.19 Billion CNY | 22.37% |
| 2015 Q4 | 1.19 Billion CNY | 0.87% |
| 2015 Q3 | 1.18 Billion CNY | 22.75% |
| 2015 Q2 | 969.08 Million CNY | 6.13% |
| 2015 Q1 | 913.08 Million CNY | -6.88% |
| 2014 Q4 | 980.53 Million CNY | 31.48% |
| 2014 Q3 | 745.77 Million CNY | 5.25% |
| 2014 FY | 980.53 Million CNY | 88.69% |
| 2014 Q2 | 708.59 Million CNY | 36.73% |
| 2014 Q1 | 518.24 Million CNY | -0.27% |
| 2013 FY | 519.66 Million CNY | 12.16% |
| 2013 Q4 | 519.66 Million CNY | 0.0% |
| 2013 Q2 | 406.49 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2012 FY | 463.32 Million CNY | 41.13% |
| 2011 FY | 328.3 Million CNY | 10.46% |
| 2010 FY | 297.2 Million CNY | 33.3% |
| 2009 FY | 222.95 Million CNY | 0.0% |